Skip to main content
. Author manuscript; available in PMC: 2024 May 1.
Published in final edited form as: Biomaterials. 2023 Mar 17;296:122093. doi: 10.1016/j.biomaterials.2023.122093

Fig. 1.

Fig. 1.

In vitro antitumor activity of PTX ± CIP2b combinatorial treatment against four different human endometrial cancer cell lines. (a–d) Cytotoxicity assay for indicated cell line following treatment for 72 hours with different concentrations of either PTX or CIP2b or different concentrations of PTX and fixed concentrations of CIP2b. (e–h), Cytotoxicity assay for indicated cell line following treatment for 72 hours with different concentrations of either PTX or CIP or CIP2b or different concentrations of PTX and fixed concentrations of either CIP or CIP2b. (i–l), Estimated IC50 values for indicated cell line following treatment with PTX ± CIP2b. (m–p), Cytotoxic synergy between PTX and CIP2b is calculated for indicated cell lines using the Combination Index (CI) method where CI values less than 1 indicate synergy. Data are plotted as mean ± SD (n=3). A one–way ANOVA with Tukey post hoc test was used for statistical analysis. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, nonsignificant.